Literature DB >> 12729348

Rates of adverse reactions to first and second doses of BCG vaccination: results of a large community trial in Brazilian schoolchildren.

I Dourado1, M H Rios, S M M Pereira, S S Cunha, M Y Ichihara, J C L Goes, L C Rodrigues, A L Bierrenbach, M L Barreto.   

Abstract

OBJECTIVE: To evaluate the incidence of adverse reactions to first and second bacille Calmette-Guérin (BCG) vaccination in schoolchildren. SETTING AND
DESIGN: Enhanced surveillance in a Brazilian trial. Suspected reactions were reported to a nurse who visited cases and completed a standard form.
RESULTS: Among 71341 schoolchildren studied, 33 reactions were reported. Of these, 25 fulfilled the criteria, resulting in a rate of one per 2854 vaccinations, with no deaths or BCG-osis. Reactions to second doses were more common than to first BCG vaccinations, but this difference was not statistically significant.
CONCLUSIONS: Adverse reactions to a second dose of BCG may be more frequent than reactions to a first dose, but they are still rare events.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12729348

Source DB:  PubMed          Journal:  Int J Tuberc Lung Dis        ISSN: 1027-3719            Impact factor:   2.373


  16 in total

1.  BCG revaccination boosts adaptive polyfunctional Th1/Th17 and innate effectors in IGRA+ and IGRA- Indian adults.

Authors:  Srabanti Rakshit; Asma Ahmed; Vasista Adiga; Bharath K Sundararaj; Pravat Nalini Sahoo; John Kenneth; George D'Souza; Wesley Bonam; Christina Johnson; Kees Lmc Franken; Tom Hm Ottenhoff; Greg Finak; Raphael Gottardo; Kenneth D Stuart; Stephen C De Rosa; M Juliana McElrath; Annapurna Vyakarnam
Journal:  JCI Insight       Date:  2019-12-19

2.  Inborn Errors of Immunity in Patients with Adverse Events Following BCG Vaccination in Brazil.

Authors:  Paula T Lyra; Edvaldo Souza; Ana Carla A Moura; Marina C Matta; Leuridan C Torres; Antonio Victor Campos Coelho; Maria Ângela W Rocha; Luiz Arraes; João Bosco Oliveira
Journal:  J Clin Immunol       Date:  2022-07-30       Impact factor: 8.542

3.  Safety and reactogenicity of BCG revaccination with isoniazid pretreatment in TST positive adults.

Authors:  Mark Hatherill; Hendrik Geldenhuys; Bernadette Pienaar; Sara Suliman; Phalkun Chheng; Sara M Debanne; Daniel F Hoft; W Henry Boom; Willem A Hanekom; John L Johnson
Journal:  Vaccine       Date:  2014-05-09       Impact factor: 3.641

4.  CLINICAL MANAGEMENT OF LOCALIZED BCG ADVERSE EVENTS IN CHILDREN.

Authors:  Thais das Neves Fraga Moreira; Maria Isabel de Moraes-Pinto; Beatriz Tavares Costa-Carvalho; Anete Sevciovic Grumach; Lily Yin Weckx
Journal:  Rev Inst Med Trop Sao Paulo       Date:  2016-11-03       Impact factor: 1.846

Review 5.  Recommendations for pediatric tuberculosis vaccination in Italy.

Authors:  Carlotta Montagnani; Susanna Esposito; Luisa Galli; Elena Chiappini; Nicola Principi; Maurizio de Martino
Journal:  Hum Vaccin Immunother       Date:  2016-03-03       Impact factor: 3.452

6.  The HyVac4 subunit vaccine efficiently boosts BCG-primed anti-mycobacterial protective immunity.

Authors:  Rolf Billeskov; Tara T Elvang; Peter L Andersen; Jes Dietrich
Journal:  PLoS One       Date:  2012-06-29       Impact factor: 3.240

7.  Gene expression and cytokine profile correlate with mycobacterial growth in a human BCG challenge model.

Authors:  Magali Matsumiya; Iman Satti; Agnieszka Chomka; Stephanie A Harris; Lisa Stockdale; Joel Meyer; Helen A Fletcher; Helen McShane
Journal:  J Infect Dis       Date:  2014-11-07       Impact factor: 5.226

8.  Boosting of cellular immunity against Mycobacterium tuberculosis and modulation of skin cytokine responses in healthy human volunteers by Mycobacterium bovis BCG substrain Moreau Rio de Janeiro oral vaccine.

Authors:  Catherine A Cosgrove; Luiz R R Castello-Branco; Tracy Hussell; Amy Sexton; Rafaela Giemza; Richard Phillips; Andrew Williams; George E Griffin; Gordon Dougan; David J M Lewis
Journal:  Infect Immun       Date:  2006-04       Impact factor: 3.441

Review 9.  Is mapping the BCG vaccine-induced immune responses the key to improving the efficacy against tuberculosis?

Authors:  R Kuan; K Muskat; B Peters; C S Lindestam Arlehamn
Journal:  J Intern Med       Date:  2020-11-19       Impact factor: 13.068

10.  Evaluation of a human BCG challenge model to assess antimycobacterial immunity induced by BCG and a candidate tuberculosis vaccine, MVA85A, alone and in combination.

Authors:  Stephanie A Harris; Joel Meyer; Iman Satti; Leanne Marsay; Ian D Poulton; Rachel Tanner; Angela M Minassian; Helen A Fletcher; Helen McShane
Journal:  J Infect Dis       Date:  2013-11-23       Impact factor: 5.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.